Kintor Pharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Kintor Pharmaceutical has a total shareholder equity of CN¥1.3B and total debt of CN¥314.9M, which brings its debt-to-equity ratio to 23.8%. Its total assets and total liabilities are CN¥1.9B and CN¥548.6M respectively.
Key information
23.8%
Debt to equity ratio
CN¥314.90m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥701.95m |
| Equity | CN¥1.33b |
| Total liabilities | CN¥548.63m |
| Total assets | CN¥1.87b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 9939's short term assets (CN¥1.3B) exceed its short term liabilities (CN¥273.9M).
Long Term Liabilities: 9939's short term assets (CN¥1.3B) exceed its long term liabilities (CN¥274.7M).
Debt to Equity History and Analysis
Debt Level: 9939 has more cash than its total debt.
Reducing Debt: 9939's debt to equity ratio has reduced from 45.2% to 23.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9939 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 9939 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 30.9% each year